Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03910660
Recruitment Status : Recruiting
First Posted : April 10, 2019
Last Update Posted : June 6, 2019
Sponsor:
Information provided by (Responsible Party):
BioXcel Therapeutics Inc

Brief Summary:
An open-label, multicenter, Phase 1b/2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with Small Cell Neuroendocrine Prostate Cancer(SCNC). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients with SCNC will be treated with BXCL701 combined with PEMBRO.

Condition or disease Intervention/treatment Phase
Prostate Cancer Neuroendocrine Tumors Small Cell Carcinoma Drug: Talabostat Mesylate plus Pembrolizumab Phase 1 Phase 2

Detailed Description:

This is an open-label, multicenter, Phase 1b/2 study to determine the composite response rate of BXCL701 administered orally and daily, combined with PEMBRO, in patients with SCNC. The study will also assess other efficacy parameters, such as rPFS, PSA PFS, OS and DOR, as well as the safety of the combined treatment. The study will consist of 2 stages:

  1. Lead-in Stage - in which the safety and tolerability of the combination of BXCL701 administered once daily (QD) on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered intravenously (IV) on Day 1 every 21 days will be assessed and confirmed in patients with SCNC. In Cycle 1, the initial dose level of BXCL701 will be 0.4 mg; if there are no safety concerns, this will be escalated to 0.6 mg.
  2. Efficacy Stage (Simon 2-Stage) - in which patients with SCNC will be treated with BXCL701 combined with PEMBRO.

Lead-in Stage:

Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. Three patients will be treated initially with 0.4 mg BXCL701 plus PEMBRO:

  • If there are no DLTs in Cycle 1, the dose of BXCL701 will be escalated to 0.6 mg in the next cohort of 3 patients.
  • If ≥1 of the 3 original patients has a DLT in Cycle 1, after a discussion between the sponsor and the investigator, either 3 patients (if 1 patient experiences a DLT) or 6 to 9 patients (if 2 or 3 patients experiences a DLT) will be added at the 0.4 mg BXCL701 dose level. For this expanded 0.4 mg cohort:

    • If less than one-third of the patients experience a DLT, consideration will be given to dose escalation to 0.6 mg BXCL701 plus PEMBRO
    • If one-third of the patients experience a DLT, the Efficacy Stage can commence
    • If more than one-third of the patients experience a DLT, a discussion will be held between the investigators and sponsors as to how to proceed.

Efficacy Stage:

After assessment of the safety and confirmation of the BXCL701/PEMBRO dose schedule (i.e., either 0.6 mg or 0.4 mg BXCL701) to be used in the subsequent stage, the Efficacy Stage will begin. Eligible SCNC patients will receive BXCL701 QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer
Actual Study Start Date : February 12, 2019
Estimated Primary Completion Date : April 2, 2022
Estimated Study Completion Date : June 2, 2022


Arm Intervention/treatment
Lead-in Stage

Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. Three patients will be treated initially with 0.4 mg Talabostat Mesylate plus PEMBRO:

  • If there are no DLTs in Cycle 1, the dose of Talabostat Mesylate will be escalated to 0.6 mg in the next cohort of 3 patients.
  • If ≥1 of the 3 original patients has a DLT in Cycle 1, after a discussion between the sponsor and the investigator, either 3 patients (if 1 patient experiences a DLT) or 6 to 9 patients (if 2 or 3 patients experiences a DLT) will be added at the 0.4 mg Talabostat Mesylate dose level. For this expanded 0.4 mg cohort.

Following dose escalation to 0.6 mg Talabostat Mesylate plus PEMBRO in 3 patients.

  • If there are no DLTs or 1/3 patients has a DLT at this dose level, the Efficacy Stage can commence.
  • If ≥1/3 patients have a DLT in Cycle 1, after a discussion between the sponsor and the investigator, 6 to 9 patients will be added at the 0.4 mg Talabostat Mesylate dose level.
Drug: Talabostat Mesylate plus Pembrolizumab

BXCL701 tablets dosage strengths include 0.2 mg tablets for oral administration.

The starting dose regimen of BXCL701 is 0.4 mg QD on Days 1-14 every 21 days. The BXCL701 dose regimen for any patient depends on the cohort enrolled during the Lead-in Stage. Additional dosing schedules 0.6 mg QD may also be evaluated during the Lead-in Stage.

On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day in the cycle.

Patients may continue to receive study treatment until the development of discontinuation criterion are met, or closure of the study by the sponsor; no maximum duration of therapy has been set.

The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 minutes on Day 1 of each 21-day cycle.

Other Name: BXCL701 plus Pembro

Efficacy Stage
After assessment of the safety and confirmation of the Talabostat Mesylate/PEMBRO dose schedule to be used in the subsequent stage, the Efficacy Stage will begin. Eligible SCNC patients will receive Talabostat Mesylate QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
Drug: Talabostat Mesylate plus Pembrolizumab

BXCL701 tablets dosage strengths include 0.2 mg tablets for oral administration.

The starting dose regimen of BXCL701 is 0.4 mg QD on Days 1-14 every 21 days. The BXCL701 dose regimen for any patient depends on the cohort enrolled during the Lead-in Stage. Additional dosing schedules 0.6 mg QD may also be evaluated during the Lead-in Stage.

On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day in the cycle.

Patients may continue to receive study treatment until the development of discontinuation criterion are met, or closure of the study by the sponsor; no maximum duration of therapy has been set.

The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 minutes on Day 1 of each 21-day cycle.

Other Name: BXCL701 plus Pembro




Primary Outcome Measures :
  1. Estimate the composite response rate of the combination of BXCL701 + PEMBRO in patients with SCNC. [ Time Frame: up to 36 months ]
    Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL12; and a greater than 50% prostate-specific antigen (PSA) decline from baseline.


Secondary Outcome Measures :
  1. Estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO [ Time Frame: up to 36 months ]
    The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro determined by radiographic evidence.

  2. Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in patients with SCNC. [ Time Frame: up to 36 months ]
    The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro

  3. Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO [ Time Frame: up to 36 months ]
    The median time frame with overall survival with the use of BXCL701 in combination with Pembro

  4. Estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO [ Time Frame: up to 36 months ]
    The timeframe in which the tumor reacts to BXCL701 in combination with Pembro

  5. Determine the risk profile of the use of BXCL701 in combination with PEMBRO. [ Time Frame: up to 36 months ]
    Determines the frequency and severity of known and unknown adverse events with the use of BXCL701 in combination with Pembro



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

All patients must satisfy the following inclusion and exclusion criteria to be eligible for entry into the trial. For patients with histologic evidence of Small Cell Neuroendocrine Prostate Cancer (SCNC) on archival tissue analysis, enrollment can proceed without obtaining pathology review of a fresh biopsy.

  1. Patient has evidence of progressive, metastatic castration-resistant disease, as defined by PCWG3 criteria.

    a. Patients with de novo small cell prostate cancer are not required to have received androgen deprivation therapy (ADT).

  2. Progression during or following completion of at least 1 prior line of systemic therapy for locally advanced or metastatic prostate cancer.
  3. Efficacy Stage Only:

    1. Patient has histologic evidence of SCNC on central pathology review of archival tumor tissue. Patients without evaluable archival metastatic tumor tissue may undergo fresh tumor biopsy during Screening.
    2. Patient has previously received at least 1 prior line of cytotoxic chemotherapy. Patients who either have refused chemotherapy or are considered unsuitable for chemotherapy may be eligible following discussion with the sponsor.
    3. Must be willing to undergo metastatic tumor biopsy during Screening. Requirement may be waived in patients without safely accessible lesion or for patients with evaluable archival metastatic tumor tissue
  4. Patient has serum testosterone <50 ng/dL during Screening except for those with de novo small cell prostate cancer.

    a. Patients with treatment-emergent SCNC without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy except for patients with de novo small cell prostate cancer.

  5. Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  6. Patient is ≥18 years of age.
  7. Patient's acute toxic effects of previous anticancer therapy have resolved to ≤Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.
  8. Patient has adequate baseline organ function, as demonstrated by the following:

    1. Serum creatinine ≤1.5 times institutional upper limit of normal (ULN) or calculated creatinine clearance >50 mL/min;
    2. Serum albumin ≥2.5 g/dL;
    3. Total bilirubin ≤1.5 × ULN;
    4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ≤5 × ULN).
  9. Patient has adequate baseline hematologic function, as demonstrated by the following:

    1. Absolute neutrophil count (ANC) ≥1.5 × 109/L.
    2. Hemoglobin ≥8 g/dL and no red blood cell transfusions during the prior 14 days.
    3. Platelet count ≥100 × 109/L and no platelet transfusions during the prior 14 days.
  10. Patient agrees to use acceptable contraceptive methods for the duration of time on the study and continue to use acceptable contraceptive methods for 6 months after the last treatment dose.
  11. Patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
  12. Patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for overall survival (OS).

Exclusion Criteria:

  1. Patient has received treatment with >2 cytotoxic chemotherapy regimens for castration-resistant prostate cancer (CRPC). Chemotherapy in the hormone-sensitive setting does not count in this assessment provided the last dose was >6 months before study entry.
  2. Patient has received external-beam radiation or another systemic anticancer therapy within 14 days or 5 half-lives, whichever is shorter, prior to study treatment.
  3. Patient has received treatment with an investigational systemic anticancer agent within 14 days prior to study drug administration.
  4. Patient has received prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed death ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T lymphocyte-associated antigen 4 [CTLA-4], OX-40, CD137).
  5. Patient has an additional active malignancy that may confound the assessment of the study endpoints. If the patient has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the sponsor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including transitional cell carcinoma, anal carcinoma, and melanoma in situ).
  6. Patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
  7. QT interval corrected for heart rate using Bazett's formula (QTcB) >480 msec at Screening.
  8. Patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study.
  9. Patient has brain or leptomeningeal metastases that are symptomatic and progressive on imaging. Patients with a history of central nervous system (CNS) metastases must have received appropriate treatment. Central nervous system imaging is not required prior to study entry unless there is a history of CNS involvement or clinical suspicion of CNS involvement. Imaging of patients with a prior history of CNS metastases should be compared to prior imaging to discern disease progression.
  10. Patient has an active autoimmune disease or Grade ≥3 pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbimazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.
  11. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of >10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 (C1D1).
  12. Patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
  13. Patient has known positive status for human immunodeficiency virus, active or chronic Hepatitis B, or Hepatitis C. Screening is not required.
  14. Patient has any medical condition which, in the opinion of the investigator, places the patient at an unacceptably high risk for toxicity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03910660


Contacts
Layout table for location contacts
Contact: Robert Sims, MD 206-719-4219 robert.sims@novellaclinical.com

Locations
Layout table for location information
United States, California
University of California, San Francisco Not yet recruiting
San Francisco, California, United States, 94158
Contact: Kaleas Johnson    415-502-5051    kaleas.johnson@ucsf.edu   
Principal Investigator: Rahul Aggarwal, MD         
United States, Colorado
The Urology Center of Colorado Recruiting
Denver, Colorado, United States, 80211
Contact: Robin Dorsey    303-762-7155    rdorsey@tucc.org   
Principal Investigator: Lawrence Karsh, MD         
United States, Florida
H. Lee Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Pallavi Purohit    813-745-7223    pallavi.purohit@moffitt.org   
Principal Investigator: Jingsong Zhang, MD         
United States, New York
White Plains Hospital - Center for Cancer Care Recruiting
White Plains, New York, United States, 10601
Contact: Joel Victor    914-849-7591    jvictor1@wphospital.org   
Principal Investigator: Dan Costin, MD         
United States, Ohio
James Cancer Hospital and Solove Research Institute at The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Laura Geran    614-688-9594    laura.geran@osumc.edu   
Principal Investigator: J. Paul Monk III, MD         
Sponsors and Collaborators
BioXcel Therapeutics Inc

Layout table for additonal information
Responsible Party: BioXcel Therapeutics Inc
ClinicalTrials.gov Identifier: NCT03910660     History of Changes
Other Study ID Numbers: BXCL701-201
First Posted: April 10, 2019    Key Record Dates
Last Update Posted: June 6, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Neuroendocrine Tumors
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Carcinoma, Small Cell
Small Cell Lung Carcinoma
Genital Diseases, Male
Carcinoma
Carcinoma, Bronchogenic
Lung Diseases
Respiratory Tract Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents